Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,169,696
  • Shares Outstanding, K 538,481
  • Annual Sales, $ 33,424 M
  • Annual Income, $ 4,090 M
  • EBIT $ 8,671 M
  • EBITDA $ 14,263 M
  • 60-Month Beta 0.45
  • Price/Sales 5.56
  • Price/Cash Flow 11.37
  • Price/Book 19.34

Options Overview Details

View History
  • Implied Volatility 21.67% (-0.84%)
  • Historical Volatility 30.66%
  • IV Percentile 16%
  • IV Rank 8.62%
  • IV High 50.37% on 04/08/25
  • IV Low 18.97% on 02/20/25
  • Expected Move (DTE 7) 7.34 (2.21%)
  • Put/Call Vol Ratio 0.39
  • Today's Volume 12,517
  • Volume Avg (30-Day) 21,904
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 167,125
  • Open Int (30-Day) 147,519
  • Expected Range 325.21 to 339.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 4.74
  • Number of Estimates 11
  • High Estimate 5.52
  • Low Estimate 4.49
  • Prior Year 5.31
  • Growth Rate Est. (year over year) -10.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
312.52 +6.36%
on 11/06/25
346.38 -4.03%
on 12/03/25
+12.55 (+3.92%)
since 11/05/25
3-Month
269.77 +23.22%
on 09/26/25
346.38 -4.03%
on 12/03/25
+48.76 (+17.19%)
since 09/05/25
52-Week
253.30 +31.23%
on 12/19/24
346.38 -4.03%
on 12/03/25
+58.08 (+21.17%)
since 12/05/24

Most Recent Stories

More News
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

NVDA : 181.82 (-0.85%)
XLV : 153.45 (-0.29%)
JNJ : 202.38 (-0.05%)
LLY : 1,008.34 (-0.61%)
IBB : 171.46 (-0.38%)
GILD : 121.50 (-0.91%)
REGN : 721.66 (-0.16%)
AMGN : 332.59 (-2.23%)
UNH : 330.93 (-0.77%)
Is Bristol-Myers Stock Underperforming the S&P 500?

Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

$SPX : 6,868.39 (+0.16%)
AMGN : 332.59 (-2.23%)
BMY : 52.10 (+0.29%)
Is Pfizer Stock Underperforming the Dow?

While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.

$DOWI : 48,013.80 (+0.34%)
AMGN : 332.59 (-2.23%)
PFE : 26.08 (+1.48%)
1 Nasdaq 100 Stock Worth Your Attention and 2 We Brush Off

1 Nasdaq 100 Stock Worth Your Attention and 2 We Brush Off

SBUX : 85.22 (+0.26%)
FAST : 41.80 (+0.12%)
AMGN : 332.59 (-2.23%)
Is Amgen Stock Underperforming the Nasdaq?

Amgen has underperformed the Nasdaq over the past year, but analysts are still fairly bullish about the biopharma stock's growth potential.

$NASX : 23,550.33 (+0.19%)
AMGN : 332.59 (-2.23%)
BMY : 52.10 (+0.29%)
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2025 Global Healthcare Conference at 1:45 p.m. ET on December 3, 2025. Peter Griffith, executive...

AMGN : 332.59 (-2.23%)
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE

THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 8 th annual Evercore ISI HealthCONx Conference at 10:00 a.m. ET on December 3, 2025. Peter Griffith,...

AMGN : 332.59 (-2.23%)
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to Chemotherapy

AMGN : 332.59 (-2.23%)
1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid

1 Unpopular Stock That Deserves a Second Chance and 2 We Avoid

QLYS : 145.72 (-2.61%)
KBH : 63.72 (-0.73%)
AMGN : 332.59 (-2.23%)
Stocks Settle Mostly Higher on Government Reopening Optimism

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.18%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.31%. December E-mini...

AMAT : 268.25 (-0.44%)
AVGO : 389.55 (+2.24%)
MRK : 100.21 (-0.67%)
RGTI : 28.63 (-4.76%)
$IUXX : 25,668.41 (+0.34%)
AMGN : 332.59 (-2.23%)
PFE : 26.08 (+1.48%)
ELV : 330.95 (-0.25%)
ASML : 1,102.10 (-0.72%)
ZNH26 : 112-175 (-0.15%)
CRWV : 88.08 (+2.72%)
VRTS : 162.14 (+1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 352.07
2nd Resistance Point 349.20
1st Resistance Point 344.68
Last Price 332.59
1st Support Level 337.29
2nd Support Level 334.42
3rd Support Level 329.90

See More

52-Week High 346.38
Last Price 332.59
Fibonacci 61.8% 310.82
Fibonacci 50% 299.84
Fibonacci 38.2% 288.86
52-Week Low 253.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar